NeuroSearch enters alliance with pharma giant GlaxoSmithKline  

Neurosearch shares jump 9% on the Copenhagen Stock Exchange as news breaks of GSK deal

It is widely reported in the Danish media that Neurosearch and GlaxoSmithKline (GSK) have entered into collaboration to discover and characterise new proprietary compounds that are mixed monoamine reuptake inhibitors for the treatment of mood disorders including depression. GSK has the option to select preclinical candidates for further development. GSK will pay Neurosearch up to USD 27 million in milestone payments as well as royalties on future sales for the first marketed compound derived from the programme. If GSK selects more than one lead compound for development, Neurosearch will receive additional milestone payments and royalties on sales.



NeuroSearch is a Danish biopharmaceutical company with compounds in clinical development and a portfolio of drug discovery programmes primarily focused on the area of central nervous system (CNS) diseases. Anglo-American GlaxoSmithKline is a world leading research-based pharmaceutical company with an estimated 7% of the world's pharmaceutical market. Its main focus areas are CNS, anti-infectives, respiratory and gastro-intestinal/metabolics. GSK has over 100,000 employees worldwide and an R&D budget of USD 4 billion. 18.8 million adults suffer from depression in the US and the worldwide antidepressant market is worth USD 15.9 billion.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×